NKTX · Nkarta, Inc.
$2.59
-0.07 (-2.63%)
At close · Aug 24
Market Cap
$183.36M
Shares
71.62M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$104.08M
+4.3%
FY2025
Operating Margin
-19433.91%
FY2019
Diluted EPS
-$1.41
+11.9%
FY2025
Operating Cash Flow
-$88.7M
+11%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | — | — | — | — | $115K | |
| $99.51M | $90.43M | $96.74M | $96.77M | $90.9M | $63.41M | $36.22M | $17.22M | |
| $32.74M | $31.57M | $31.45M | $34.88M | $28.06M | $23.02M | $15.29M | $5.25M | |
| $9.6M | $9.2M | $9.2M | $5.9M | $2.6M | $1.8M | $800K | $400K | |
| — | $4.95M | — | — | — | — | — | — | |
| $132.25M | $122M | $128.19M | $131.65M | $118.96M | $86.43M | $51.51M | $22.46M | |
| -$132.25M | -$122M | -$128.19M | -$131.65M | -$118.96M | -$86.43M | -$51.51M | -$22.35M | |
| — | — | — | — | — | — | — | -19433.91% | |
| -$122.65M | -$112.8M | -$118.99M | -$125.75M | -$116.36M | -$84.63M | -$50.71M | -$21.95M | |
| $14.93M | $17.91M | $19.4M | $14.15M | $5.12M | $354K | -$39.85M | $1.27M | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$117.32M | -$104.08M | -$108.79M | -$117.5M | -$113.84M | -$86.08M | -$91.36M | -$21.08M | |
| — | — | — | — | — | — | — | -18326.96% | |
| -$118.11M | -$104.35M | -$108.12M | -$116.81M | -$114.37M | -$86.23M | -$91.36M | -$21.08M | |
| USD/shares | — | -$1.41 | -$1.60 | -$2.40 | -$2.61 | -$2.62 | — | — |
| USD/shares | — | -$1.41 | -$1.60 | -$2.40 | -$2.61 | -$2.62 | — | — |
| shares | — | 73.99M | 67.87M | 49.01M | 43.63M | 32.86M | 16.81M | 1.46M |
| shares | — | 73.99M | 67.87M | 49.01M | 43.63M | 32.86M | 16.81M | 1.46M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.98×
EV/EBIT
—
Peer median 10.07×
P/E (TTM)
—
Peer median 9.36×
Peer medians compare against the 303 similar-size Biotechnology companies (of 533 listed).
Key facts
CIK
1787400
CUSIP
65487U108
13F (30d)
119 filings
119 filers
Visit website
Investor relations